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Abstract
Introduction: Ewing’s sarcoma belongs to a spectrum of neoplastic diseases known as Ewing’s family of tumors.
This family of tumors is usually seen in osseous sites. Ewing’s sarcoma of the cervix is extremely rare, with only 18 cases
reported in the English literature. The immunohistochemical profile of Ewing’s sarcoma overlaps with other malignancies
like small cell carcinoma. The rarity and complex pathologic picture of Ewing’s sarcoma of the cervix creates the potential
for misdiagnosis. Hence, we believe this case needs to be reported to add to the available literature.
Case presentation: A 49-year-old white Caucasian woman presented with vaginal bleeding. A pelvic examination
revealed a cystic lesion arising from her cervix. Examination of a biopsy specimen revealed a poorly differentiated
neoplasm, with sheets of small hyperchromatic cells, staining weakly for neuroendocrine markers. She was diagnosed
with small cell carcinoma and started on concurrent chemotherapy and radiation. However, additional positive
immunostaining for CD99 was strongly suggestive of Ewing’s sarcoma. Fluorescence in situ hybridization revealed ESWR1
gene rearrangement, confirming Ewing’s sarcoma. Our patient underwent surgery, which confirmed stage IIB Ewing’s
sarcoma. She received adjuvant chemotherapy but died from progressive metastatic disease after four cycles.
Conclusion: With early diagnosis and appropriate treatment, Ewing’s sarcoma of the cervix can be a potentially curable
disease. However, owing to overlapping clinical and histopathological features, the diagnosis poses a challenge to
oncologists and pathologists. This article guides pathologists to consider Ewing’s sarcoma in the differential diagnosis of
small cell carcinoma with weak staining for neuroendocrine markers. This literature review will benefit oncologists
encountering this rare entity.
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Introduction
Ewing’s sarcoma and peripheral neuroectodermal
tumor (PNET) are the same entity, displaying varying
degrees of neuroectodermal differentiation. They arise
from mesenchymal progenitor cells and are part of a
spectrum of neoplastic diseases, known as Ewing’s
family of tumors (EFT) [1]. EFT are characterized by
reciprocal translocation between chromosomes 11 and
22, t (11; 22), and are usually seen in osseous sites, both
axial and appendicular. Extra-osseous presentations are
uncommon, with specifically PNET of the female genital
tract being very rare. The most common site of PNET in
the female genital tract is the ovary, with the uterine cor-
pus being the second most common. Primary PNET of
the cervix and vulva are extremely rare. In this article, we
present a case of primary PNET tumor of the cervix. The
rarity of this entity can lead to diagnostic difficulties. In
our case, it was initially diagnosed as a neuroendocrine
small cell carcinoma of the cervix. We also summarize a
literature review of all the cases reported in the English
language.
Case presentation
A 49-year-old gravida 2, para 2, perimenopausal woman
presented with vaginal bleeding. A pelvic examination
revealed a cystic lesion arising from her cervix.
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Examination of a biopsy specimen revealed a poorly dif-
ferentiated neoplasm involving the cervical stroma, with
sheets of small hyperchromatic cells with slightly irregu-
lar nuclei, stippled chromatin, inconspicuous nucleoli,
minimal cytoplasm, necrosis, and numerous mitotic fig-
ures (Figs. 1 and 2). Immunostaining showed the samples
were weakly positive for neuron-specific enolase, CD56,
and synaptophysin, and negative for pancytokeratin, CK7,
CK20, and CD45. Magnetic resonance imaging (MRI) of
the pelvis showed a 5.3 × 4.8 × 6.6 cm irregular, enhancing
mass arising from her cervix, with involvement of the
adjacent vagina and parametrium (Fig. 3). A positron
emission tomography–computed tomography (PET/CT)
scan revealed that the mass was hypermetabolic with a
standard uptake value of 5.5, and did not demonstrate any
distant metastatic disease.
The pathologic diagnosis was invasive malignant
small round blue cell tumor most consistent with
small cell carcinoma. She completed two cycles of cis-
platin and etoposide and a planned course of
5,040 cGy over 28 fractions of 180 cGy each, which
led to resolution of the vaginal bleeding. However,
owing to the only weak staining for the neuroendo-
crine markers, further immunostaining was per-
formed. Stains for S-100, CD3, CD20, TTF1, and
desmin were negative whereas that for CD99 was
strongly positive (Fig. 4). Diffuse membranous positivity
for CD99 led to a diagnosis of Ewing’s sarcoma/PNET and
ruled out small cell carcinoma. Fluorescence in situ
hybridization revealed ESWR1 gene rearrangement in
90 % of cells, confirming the diagnosis of Ewing’s sarcoma.
Subsequently, chemotherapy was discontinued and our pa-
tient underwent total hysterectomy and bilateral salpingo-
Fig. 1 Medium power (200×) hematoxylin and eosin stain showing
sheets of small tumor cells, focal necrosis, and a delicate
vascular network
Fig. 2 High power (400×) hematoxylin and eosin stain showing
small cells with focal necrosis and mitotic activity
Fig. 3 Magnetic resonance imaging of the pelvis: sagittal view.
An enhancing mass is visible in the anterior cervix
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oophorectomy, upper vaginectomy, and resection of the
parametrium. Surgical pathology showed stage IIB Ewing’s
sarcoma involving her cervix and extending into the
right parametrium. Her endometrium, ovaries, and
fallopian tubes were unremarkable and margins were
free of tumor.
She was started on chemotherapy with vincristine
(2 mg/m2 on day 1), doxorubicin (Adriamycin; 75 mg/
m2), and cyclophosphamide with mesna (1,200 mg/m2
on day 1), alternating with ifosfamide plus mesna
(1,800 mg/m2 days 1–5) and etoposide (100 mg/m2)
every 3 weeks. A PET scan done after two cycles demon-
strated no recurrence of the tumor. After four cycles,
9 months from initial diagnosis, she developed acute
renal failure. CT scans showed evidence of metastases to
her lumbar spine, pelvis, and bladder. Nephrostomy
tubes were placed, which improved renal function. Two
weeks later she presented with distal colonic obstruction
secondary to an extensive pelvic tumor. Exploratory
laparotomy and a diverting loop colostomy were done.
One week later her disease progressed with new lung
metastases, which led to clinical deterioration and death,
with an overall survival of 10 months.
Discussion
Ewing’s sarcoma/PNET of the cervix is an extremely rare
entity. Our review shows that there have been only 18
cases reported so far in the English literature; we report
the 19th case (Table 1). In two cases, PNET was reported
in association with another malignancy. Horn et al. re-
ported PNET with squamous cell carcinoma of the cervix,
and Tsao et al. reported carcinoma in addition to PNET,
and described their case as a “carcinosarcoma” [2, 3]. The
ages at presentation ranged between 19 and 60 years, with
the mean age being 39.
The most common symptom reported was irregular
vaginal bleeding. Other symptoms included dysuria, lower
abdominal pain, vaginal discharge, and in one case, urin-
ary frequency. The most common physical findings were
nodular lesions extending into the anterior vaginal wall
and enlarged uterus. The vaginal bleeding with enlarged
uterus led to the preliminary diagnosis of fibroid in two
patients [3, 4]. One patient had vaginal stenosis and
necrotic tissue on the cervix [5].
Stage was not reported in three cases. Ten (62.5 %)
patients were stage IB1 or IB2, one (6.25 %) stage
IIA, two (12.5 %) stage IIB, one (6.25 %) stage IIIB,
and two stage IV (12.5 %).
In the reported cases, multiple imaging modalities in-
cluding ultrasound, CT, and MRI were used for diagno-
sis and staging. Our review shows that PNET tumors are
highly fludeoxyglucose avid. PET scan may be a useful
imaging modality in diagnosis, staging, and monitoring
response to therapy.
The diagnosis of EFTs is difficult by routine micros-
copy because they have small blue cell morphology that
can be seen in several malignancies. On histology exam-
ination, there are sheets of small blue cells with “stippled
salt and pepper chromatin” in the nuclei and absence of
nucleoli [6]. Necrosis and nuclear molding of adjacent
cells is common. Additionally, the cells easily become
crushed during processing of the specimen, producing
smudged and streaked extra nuclear chromatin (crush
artifact). Small round blue cells can be seen in a wide var-
iety of malignancies which can be remembered using the
pneumonic “LEMON” (lymphoblastic lymphoma, Ewing’s
sarcoma, medulloblastoma, oat cell/small cell neuroendo-
crine, and neuroblastoma). Other soft tissue sarcomas and
rhabdomyosarcoma should also be considered in the
differential diagnosis. Lymphoblastic lymphomas closely
resemble PNET because they have sheets of small cells
with a lack of glandular or squamous differentiation.
Immunohistochemistry is critical in the diagnosis. Small
cell neuroendocrine carcinomas are usually positive for
chromogranin, synaptophysin, and neuron-specific enolase,
and overlap highly with PNET. The vast majority of EFTs
express high levels of a cell surface glycoprotein CD99 or
MIC2 surface antigen that is encoded by the CD99
Fig. 4 High power (400×) immunohistochemical diffuse and
membranous CD99 positivity
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Table 1 Clinical and pathologic features, diagnosis, treatment, and outcome of peripheral neuroectodermal tumors of the cervix
Author Age Symptoms Diagnosis Stage Surgery Chemotherapy/intent of chemotherapy Radiation
therapy
Outcome
1 Russin et al. 1987 [21] 60 Vaginal bleeding Path/IHC IB TAH + BSO + LND VAC for 6 weeks/adjuvant Yes Alive at 16 months, NED
2 Sato et al. 1996 [22] 44 Irregular vaginal
bleeding
Path/IHC IB2 TAH + BSO + LND, second




No Alive 6 months, NED
3 Horn et al. 1997 [2] 26 Suspect cervical
smear
Path/IHC IB1 TAH + BSO + LND No adjuvant chemotherapy; had lung
metastases 3 years after diagnosis,
received 5FU and cisplatin/palliative
RT to
metastases
Died 4.2 years after
diagnosis
4 Cenacchi et al. 1998 [15] 36 Irregular vaginal
bleeding
Path/IHC/RT-PCR IB2 TAH without BSO No No Alive 18 months, NED
5 Pauwels et al. 2000 [14] 45 Irregular vaginal
bleeding
Path/IHC/FISH IB2 TAH No Pelvic RT Alive 42 months, NED
6 Tsao et al. 2001 [3] 24 Vaginal bleeding,
urinary frequency
Path/IHC TAH + transposition of
ovaries + LNS
Two cycles, VAC alternating with IE,
neoadjuvant and adjuvant
Yes Alive 24 moths, NED
7 Malpica and Moran 2002 [6] 35 Vaginal bleeding Path/IHC IB1 TAH + BSO + LND Adjuvant chemotherapy/regimen
not reported
No Alive 5 months, NED
8 Malpica and Moran 2002 [6] 51 Vaginal bleeding Path/IHC IB2 TAH + BSO + LND Adjuvant chemotherapy/regimen
not reported





Path/IHC IB2 TAH without adnexectomy Six courses of DIME/neoadjuvant; five
courses of VIA/adjuvant
No Alive 27 months, NED
10 Goda et al. 2007 [19] 19 Vaginal bleeding,
discharge
No Induction VAC, planned for further
consolidation after RT
Yes Alive, on treatment
when reported
11 Farzaneh et al. 2011 [23] 43 Purulent vaginal
discharge
Path/IHC IB2 TAH + BSO + LNS 12 weeks of VAC alternating with
IE/neoadjuvant
No Alive 4 years, NED
12 weeks of VAC alternating with
IE/adjuvant
12 Benbrahim et al. 2012 [9] 25 Irregular vaginal
bleeding
Path/IHC IIb Coniztion with
brachytherapy
Four cycles of Adriamycin and
Cytoxan/neoadjuvant
Yes Alive 8 years, NED
13 Arora et al. 2012 [4] 23 Irregular bleeding,
dysuria
Path/IHC TAH + BSO + LND One cycle of CAV, followed by two
cycles of cis/VP16/neoadjuvant
Yes Alive 4 years, NED
14 Masoura et al. 2012 [16] 23 Irregular bleeding,
abdominal pain
Path/IHC/RT-PCR IV TAH + BSO Cisplatin once/adjuvant No. Died, 12 days
15 Li et al. 2013 [5] 27 Contact bleeding,
abdominal pain
Path/IHC IIIB Unresectable VAC alternating with IE/definitive
chemotherapy
Yes Alive at 6 months, NED
16 Khosla et al. 2014 [24] 28 10 weeks pregnant
with vaginal bleeding
and pelvic pain
Path/IHC IB2 Termination of pregnancy,
TAH + BSO + LNS
Adriamycin, IE, for total of
6 weeks/adjuvant












Table 1 Clinical and pathologic features, diagnosis, treatment, and outcome of peripheral neuroectodermal tumors of the cervix (Continued)
17 Xiao et al. 2014 [18] 52 Vaginal bleeding,
uterine enlargement
Path/IHC IIA TAH + BSO + LND Two courses of PVB Pelvic recurrence
6 months, DOD 9 months
18 Xiao et al. 2014 [18] 59 Cervix prolapse, vaginal
bleeding
Path/IHC IVB TAH + BSO + LND None DOD
19 Present case 49 Vaginal bleeding, lower
abdominal pain
Path/IHC/FISH IIB TAH + BSO Cisplatin/Etoposide with RT due
to diagnosis of small cell VAC
alternating with IE/adjuvant
Yes Died, 10 months
5FU 5-fluorouracil, BSO bilateral salpingo oophorectomy, DIME Doxorubicin, Ifosfamide, Mesna, Etoposide, DOD died of disease, FISH fluorescent in situ hybridization, IE Ifosfamide, Etoposide, IHC immunohistochemical
studies, LND/LNS pelvic lymphadenectomy/lymph node sampling, LSO left-sided oophorectomy, NED no evidence of disease, PVB Cisplatin, Vincristine, Bleomycin, RT radiation therapy, RT-PCR reverse transcriptase












(MIC2X) gene [7, 8]. The finding of membrane-localized
MIC2 expression in a small blue cell malignancy is a sensi-
tive diagnostic marker for the EFTs. MIC2 lacks specificity
because other tumors, like rhabdomyosarcoma, can be
MIC2 positive. However, small cell carcinomas are negative
for MIC2. Benbrahim et al. reported a case of cervical PNET
that was initially misdiagnosed as lymphoma [9]. Lymphoid
markers, leucocyte common antigen, CD20, and CD3 can
be utilized to differentiate lymphoma from PNET [9].
Molecular genetic characterization of chromosomal
anomalies specific to EFT has led to increased detection.
The characteristic signature translocation involving the
EWS gene at 22q12.2 and various erythroblast transcrip-
tion specific-family genes, like FLI (friend leukemia virus
integration 1) at 11q24.1-q24.3, is seen in 85–90 % of
cases [10, 11]. ESWR encodes a multifunctional protein
that regulates multiple cellular processes. FLI1 encodes
the FLI1 protein, which controls cellular development,
proliferation, and carcinogenesis [12]. The EWSR1–ERG
translocation [t (21; 22) (q22; q12)] is present in 5–10 %
of EFTs, while other translocations are less common [13].
Most of the cases reported were diagnosed based on
histopathology and immunohistochemistry (Table 1).
Cytogenetic analysis [14] was done in one case. Fluores-
cent in situ hybridization [14] was used in two cases in-
cluding our case, while reverse transcriptase polymerase
chain reaction [15, 16] was used in two cases.
Currently there is no uniformity of treatment, owing
to the rarity of this neoplasm. Snijders-Keilholz et al.
recommended a multidisciplinary approach similar to
that used in osseous PNETs with induction chemother-
apy, surgery, adjuvant chemotherapy, and radiation [17].
When surgery is feasible, wide excision performed at a
sarcoma center is preferable.
Most patients (Table 1) with early stage disease
underwent total abdominal hysterectomy and bilateral
salpingo-oophorectomy. Pelvic lymph node dissection
was performed in 11 out of 19 cases. Of these 11
cases, eight patients are alive without recurrence, the
outcome of two cases is unknown, and one patient
died from metastatic disease 4 years later. Of the
eight cases that did not use lymph node dissection,
two tumors were inoperable owing to stage IIIB [5]
and IV [16] disease. The stage of one patient is un-
known. The remaining five cases were early stage
(three stage I B2, two stage IIB). Of these five cases,
one patient did not receive any chemotherapy and
died 4 years later. Our patient (stage IIB) died
10 months later despite chemotherapy and radiation.
The other three cases received chemotherapy and are
alive without relapse. The contribution of Pelvic
lymph node dissection (PLND) to overall survival, es-
pecially in patients who had chemoradiation, is
unclear.
Chemotherapy was used in 16 of the 19 cases (Table 1).
Two patients who were metastatic at diagnosis received
palliative chemotherapy. Although adjuvant chemother-
apy was used in the earlier reported cases, a combined
regimen of neoadjuvant and adjuvant chemotherapy has
been used frequently in recent years, with favorable re-
sults. The chemotherapy regimens and schedules used
varied considerably. The use of ifosfamide and etoposide
alternating with vincristine, doxorubicin (Adriamycin)
and cyclophosphamide, which is the regimen of choice
for Ewing’s sarcoma of the bone, has increased in recent
years with good outcomes. The overall survival appears
to have dramatically improved with the use of
chemotherapy.
Eight of 19 patients (Table 1) received radiation ther-
apy. The intent of radiation was palliative in one case,
definitive in three, and adjuvant in four. The definitive
chemoradiation given to our patient was part of the
small cell carcinoma regimen owing to an initial small
cell diagnosis, but she subsequently developed pelvic
recurrence 9 months after diagnosis. Another case death
from pelvic recurrence 9 months after diagnosis was
reported by Xiao et al. [18], but the authors did not
report if radiation was given. Radiation doses ranged
from 40 to 55 Gy with the fractionation schedule of
180–200 cGy over 4–5 weeks. Overall, we conclude that
adjuvant radiation may have a role in preventing local
recurrence and should be considered when appropriate.
The follow-up of these cases ranged between 5 months
and 8 years, with 15 of the 19 cases being alive and
recurrence-free at the time of follow-up. Two patients
died of metastatic disease 12 days and 4.2 years after
presentation, respectively. Our patient developed meta-
static disease while on adjuvant chemotherapy and died
10 months after diagnosis. The outcome of a case re-
ported by Goda et al. [19] is unknown.
The best outcomes were noted in patients who under-
went tri-modality therapy with surgery, chemotherapy,
and radiation; although owing to the paucity of cases the
best approach is still unknown.
Similar to skeletal Ewing’s sarcoma, the most unfavorable
prognostic factor is the presence of distant metastasis, with
stage IV disease being universally fatal. A recent review by
Baldini et al. [20] suggested that age may be a prognostic
factor in survival and elderly patients do poorly.
Conclusion
It is important to identify these rare cases of Ewing’s sar-
coma to provide early and appropriate treatment. With
prompt diagnosis and aggressive multimodality treatment,
PNET of the cervix appears to be a potentially curable
disease. Once diagnosis is made, referral to a tertiary care
center with dedicated multidisciplinary tumor boards and
special expertise in sarcoma management is recommended.
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Hopefully, identification of more cases in the future may
help establish a meaningful pattern of behavior and guide
clinical management of this rare entity.
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